NuVue Therapeutics

NuVue Therapeutics is a preclinical-stage biotechnology company specializing in the development of image-guided, targeted therapies for oncology. The company's core technology is a proprietary liposomal delivery platform that enables the visualization of drug accumulation within tumors, facilitating a precision medicine approach. By combining therapeutic payloads such as siRNA with imaging capabilities, NuVue aims to enhance the delivery and efficacy of treatments for hard-to-treat solid tumors. The company's lead research programs focus on indications such as ovarian and pancreatic cancers, leveraging biomarkers like EphA2 for targeted delivery. NuVue was founded as a spin-out from the University of Texas MD Anderson Cancer Center and has participated in the Texas Medical Center's TMCx accelerator program.